CN Patent

CN113321668A — 塞尔帕替尼的合成

Assigned to Jiangsu Huiju Pharmaceutical Co ltd · Expires 2021-08-31 · 5y expired

What this patent protects

本发明涉及塞尔帕替尼中间体合成。具体为提供一种制备塞尔帕替尼中间体6‑烷氧基‑4‑(6‑氟吡啶‑3‑基)吡唑并[1,5‑a]吡啶‑3‑甲腈的方法。该方法的策略为提前将2‑氟吡啶基团在形成吡唑并[1,5‑a]吡啶环前引入，提高了反应效率和选择性。

USPTO Abstract

本发明涉及塞尔帕替尼中间体合成。具体为提供一种制备塞尔帕替尼中间体6‑烷氧基‑4‑(6‑氟吡啶‑3‑基)吡唑并[1,5‑a]吡啶‑3‑甲腈的方法。该方法的策略为提前将2‑氟吡啶基团在形成吡唑并[1,5‑a]吡啶环前引入，提高了反应效率和选择性。

Drugs covered by this patent

Patent Metadata

Patent number
CN113321668A
Jurisdiction
CN
Classification
—
Expires
2021-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Huiju Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.